CTI BioPharma Corp. / Fundamentals
Income statement
- Net revenue
€65.01M - Cost of goods sold
€3.83M - Gross profit
€61.18M - SG&A expenses
€76.10M - R&D expenses
€33.51M - EBITDA
-€43.68M - D&A
€2.59M - EBIT
-€46.27M - Interest expenses
€14.39M - EBT
-€59.41M - Tax expenses
€6.67M - Net income
-€66.08M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€8.46M - Changes in working capital
-€30.84M - Operating cash flow
-€70.63M - Capex
€0.00 - Other investing cash flow
-€21.45M - Net investing cash flow
-€50.28M - Total cash dividends paid
€0.00 - Issuance of common stock
€46.53M - Debt repayment
€0.00 - Other financing cash flow
€20.59M - Net financing cash flow
€58.53M - Foreign exchange effects
€0.00 - Net change in cash
-€62.37M - Cash at end of period
€20.77M - Free cash flow
-€70.63M
Balance sheet
- Cash and cash equivalents
€20.77M - Cash and short-term investments
€50.63M - Total receivables
€19.70M - Inventory
€666.67K - Other current assets
€3.18M - Total current assets
€74.18M - Property, plant & equipment
€1.62M - Goodwill
€0.00 - Intangible assets
€19.48M - Long-term investments
€0.00 - Other non-current assets
€1.05M - Total non-current assets
€22.15M - Total assets
€96.33M - Accounts payable
€1.74M - Short-term debt
€41.26M - Other current liabilities
€15.54M - Total current liabilities
€58.54M - Long-term debt
€0.00 - Deferred tax liabilities
€0.00 - Other non-current liabilities
€59.54M - Total non-current liabilities
€59.54M - Total liabilities
€118.08M - Common stock
€113.26K - Retained earnings
-€2.17B - Other equity
-€9.44K - Total equity
-€21.75M - Total liabilities and shareholders' equity
€96.33M
Company information
- Market capitalization
€1.02B - Employees
127 - Enterprise Value
€1.22B
Company ratios
- Gross margin
-
94.1% Much worse than peer group: 852,881,786,733,653,100.0% - EBITDA margin
-
-67.2% Much worse than peer group: 5,790,935,712,443,298,400.0% - EBIT margin
-
-71.2% Much worse than peer group: 1,962,152,429,646,178,000.0% - EBT margin
-
-91.4% Much worse than peer group: 5,945,639,739,783,930,000.0% - Net margin
-
-101.6% Much worse than peer group: 5,955,321,461,527,878,000.0% - ROE
-
303.8% Much better than peer group: -46.5% - ROA
-
-68.6% Even with peer group: -70.5% - Asset turnover
-
67.5% Much better than peer group: 18.3% - FCF margin
-
-108.6% Much better than peer group: -3,270,616,399,685,439,000.0% - FCF yield
-6.9% - Efficiency ratio
167.2% - Net sales per employee
-
€511.89K - Net income per employee
-
-€520.29K